NYSE:LLYPharmaceuticals
Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far?
Wondering if Eli Lilly is still worth buying after its monster run, or if the upside has already been priced in? You are not alone, and that is exactly what this article aims to unpack.
The stock has climbed 1.7% over the last week, 1.0% in the past month, and is up a hefty 32.1% year to date, building on a 31.2% gain over the last year and an astonishing 531.7% over five years.
A big part of this momentum has been driven by excitement around Eli Lilly's obesity and diabetes treatments,...